Kodiak Sciences Inc.
No SEC Form 4 filings for $KOD in the last 30 days.
See all $KOD insider activity →Kodiak Sciences (KOD) reported Q2 2026 results, highlighting three upcoming Phase 3 trial readouts by late 2026. The biotech's cash burn widened to $65.6M, with $125.9M in cash remaining. Trials focus on Zenkuda and KSI-501 for eye diseases, targeting a $15B market. Short interest is high at 25.94% of float.
Kodiak Sciences reported a Q2 2026 net loss of $65.6M, or $1.05 per share, for the quarter ended June 30, 2026, and cash and cash equivalents of $125.9M. R&D rose to $56.1M. The company reiterated Phase 3 readouts: DAYBREAK in Sept 2026 and PEAK Pivotal Analysis 1 in Dec 2026.
Kodiak Sciences Inc. (KOD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June
Over the past 7 days, alphai's AI scored 1 news story mentioning KOD (Kodiak Sciences Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent KOD coverage spans financial news, earnings and insider activity.
Earnings miss and high cash burn increase downside risk; upcoming trial readouts add binary upside potential.
The filing updates near-term clinical catalysts (DAYBREAK in Sep 2026, PEAK Pivotal Analysis 1 in Dec 2026) alongside cash runway and cost trajectory, shaping funding and probability-of-success expectations.
The filing updates near-term clinical catalysts and confirms cash runway into 2027, which can shift risk/reward for late-stage biotech positioning.
Enrollment start advances KSI-501’s second registrational Phase 3 program, supporting a longer-dated catalyst path toward topline data.
Operational execution and cashflow timing are the key drivers: crushing/DMS issues in May, improved June throughput, and interim shipment payments.
alphai scores every news story that mentions KOD with an AI model for sentiment and relevance, and aggregates insider trades from Kodiak Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kodiak Sciences (KOD) reported Q2 2026 results, highlighting three upcoming Phase 3 trial readouts by late 2026. The biotech's cash burn widened to $65.6M, with $125.9M in cash remaining. Trials focus on Zenkuda and KSI-501 for eye diseases, targeting a $15B market. Short interest is high at 25.94% of float.
3 min readKodiak Sciences reported a Q2 2026 net loss of $65.6M, or $1.05 per share, for the quarter ended June 30, 2026, and cash and cash equivalents of $125.9M. R&D rose to $56.1M. The company reiterated Phase 3 readouts: DAYBREAK in Sept 2026 and PEAK Pivotal Analysis 1 in Dec 2026.
1 min readKodiak Sciences Inc. (KOD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June
4 min readKodiak Sciences (Nasdaq: KOD) said it enrolled the first patients in its global Phase 3 ALTO trial of KSI-501 for diabetic macular edema. The study compares KSI-501 5 mg versus aflibercept 2 mg, aiming to show superiority and testing dosing intervals up to six months. About 910 patients are planned, with primary visual acuity endpoints at weeks 48-52.
3 min readKodal Minerals (AIM: KOD) reported Bougouni lithium project results for the quarter ended 30 June 2026. Spodumene concentrate output was 26,174 DMT at 5.34% Li2O, with 53,195 DMT year to date. A US$13m initial repayment was made by operator LMLB to KMUK. Third shipment (~20,400 DMT) arrived in Hainan; interim payment was $34.4m for 95% of estimated value.
4 min readMarketBeat reports that eight brokerages covering Kodiak Sciences (NASDAQ:KOD) give an average “Moderate Buy” rating, with one sell, one hold, and six buy ratings. The average 1-year price target is $42.14. UBS raised its target to $80; HC Wainwright set $58; Chardan lifted to $61. KOD shares opened at $32.94 and last reported EPS of ($0.94) for May 7, slightly below consensus.
3 min readKodiak Sciences CFO John A. Borgeson sold 30,000 shares on June 4, 2026 via option exercise and immediate open-market sale, according to an SEC Form 4. The weighted average purchase price was $34.10. His direct holdings fell 12.40% to 211,930 shares, leaving about $7.24 million in direct common stock value. The sale followed a 10b5-1 plan.
4 min readBORGESON JOHN A. (Chief Financial Officer) sold 4,104 shares of Kodiak Sciences Inc. (KOD) at $34.67 ($0.14M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readBORGESON JOHN A. (Chief Financial Officer) sold 25,896 shares of Kodiak Sciences Inc. (KOD) at $34.01 ($0.88M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readKodiak Sciences Inc. announced positive results from its GLOW2 Phase 3 study of Zenkuda (tarcocimab tedromer) for treating diabetic retinopathy, leading to a significant increase in its stock price. The study met its primary endpoint, showing substantial improvement in diabetic retinopathy severity and an 85% risk reduction in sight-threatening complications. The company plans to expedite its Biologics License Application submission based on these findings, although InvestingPro analysis suggests the stock is currently overvalued.
4 min read
